Results · Apr-Jun 2026
Suven Life Sciences Q1 FY27 results
Sales grew 91% to ₹3.6 crore from ₹1.9 crore in Apr-Jun 2025.
Operating profit was −₹133 crore, an operating margin of −3715.9% (down 997.3 points from a year ago).
The net loss widened to ₹128 crore from ₹51.5 crore.
Against Jan-Mar 2026: sales +135%, loss widens.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 3.6 | 1.9 | +91% |
| Operating profit (EBITDA) | -132.5 | -50.7 | n/m |
| Operating margin | −3715.9% | −2718.6% | −997.3 pts |
| Net profit | -127.6 | -51.5 | loss widens |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.